Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients (NCT02162888) | Eagle Pharmaceuticals, Inc. | 2013-11-01 |
Track Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate automatically
Every clearance here is in the API, with alerts when new ones post.